Does the media refer more to EXEL or ABCL?

In the previous week, Exelixis had 18 more articles in the media than AbCellera Biologics. MarketBeat recorded 25 mentions for Exelixis and 7 mentions for AbCellera Biologics. Exelixis' average media sentiment score of 1.34 beat AbCellera Biologics' score of 0.65 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 20 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ABCL or BMRN?

In the previous week, BioMarin Pharmaceutical had 9 more articles in the media than AbCellera Biologics. MarketBeat recorded 16 mentions for BioMarin Pharmaceutical and 7 mentions for AbCellera Biologics. BioMarin Pharmaceutical's average media sentiment score of 1.32 beat AbCellera Biologics' score of 0.65 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 13 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ABCL or HALO?

In the previous week, Halozyme Therapeutics had 12 more articles in the media than AbCellera Biologics. MarketBeat recorded 19 mentions for Halozyme Therapeutics and 7 mentions for AbCellera Biologics. Halozyme Therapeutics' average media sentiment score of 1.27 beat AbCellera Biologics' score of 0.65 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 14 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARWR or ABCL?

In the previous week, Arrowhead Pharmaceuticals had 10 more articles in the media than AbCellera Biologics. MarketBeat recorded 17 mentions for Arrowhead Pharmaceuticals and 7 mentions for AbCellera Biologics. Arrowhead Pharmaceuticals' average media sentiment score of 1.18 beat AbCellera Biologics' score of 0.65 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 15 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MDGL or ABCL?

In the previous week, Madrigal Pharmaceuticals had 9 more articles in the media than AbCellera Biologics. MarketBeat recorded 16 mentions for Madrigal Pharmaceuticals and 7 mentions for AbCellera Biologics. Madrigal Pharmaceuticals' average media sentiment score of 1.33 beat AbCellera Biologics' score of 0.65 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 14 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

AbCellera Biologics (ABCL) Competitors

$12.40 +0.16 (+1.31%)

Closing price 08/27/2026 04:00 PM Eastern

Extended Trading

$12.42 +0.02 (+0.19%)

As of 08/27/2026 07:57 PM Eastern

Compare

ABCL vs. EXEL, BMRN, HALO, ARWR, and MDGL

Should you buy AbCellera Biologics stock or one of its competitors? AbCellera Biologics's main competitors and comparable companies include Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Halozyme Therapeutics (HALO), Arrowhead Pharmaceuticals (ARWR), and Madrigal Pharmaceuticals (MDGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AbCellera Biologics compare to Exelixis?

Exelixis (NASDAQ:EXEL) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

85.3% of Exelixis shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Exelixis has a net margin of 35.33% compared to AbCellera Biologics' net margin of -248.83%. Exelixis' return on equity of 42.17% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
AbCellera Biologics	-248.83%	-17.49%	-12.36%

Exelixis currently has a consensus target price of $50.07, suggesting a potential downside of 9.40%. AbCellera Biologics has a consensus target price of $12.83, suggesting a potential upside of 3.49%. Given AbCellera Biologics' stronger consensus rating and higher possible upside, analysts plainly believe AbCellera Biologics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Exelixis has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	5.90	$782.57M	$3.18	17.38
AbCellera Biologics	$75.13M	50.61	-$146.41M	-$0.54	N/A

Exelixis has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

In the previous week, Exelixis had 18 more articles in the media than AbCellera Biologics. MarketBeat recorded 25 mentions for Exelixis and 7 mentions for AbCellera Biologics. Exelixis' average media sentiment score of 1.34 beat AbCellera Biologics' score of 0.65 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	20 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Exelixis beats AbCellera Biologics on 11 of the 16 factors compared between the two stocks.

How does AbCellera Biologics compare to BioMarin Pharmaceutical?

AbCellera Biologics (NASDAQ:ABCL) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

AbCellera Biologics has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

BioMarin Pharmaceutical has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	50.61	-$146.41M	-$0.54	N/A
BioMarin Pharmaceutical	$3.22B	3.92	$348.90M	$0.37	176.46

61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by company insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, BioMarin Pharmaceutical had 9 more articles in the media than AbCellera Biologics. MarketBeat recorded 16 mentions for BioMarin Pharmaceutical and 7 mentions for AbCellera Biologics. BioMarin Pharmaceutical's average media sentiment score of 1.32 beat AbCellera Biologics' score of 0.65 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	13 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioMarin Pharmaceutical has a net margin of 2.14% compared to AbCellera Biologics' net margin of -248.83%. BioMarin Pharmaceutical's return on equity of 5.32% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-248.83%	-17.49%	-12.36%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

AbCellera Biologics currently has a consensus target price of $12.83, indicating a potential upside of 3.49%. BioMarin Pharmaceutical has a consensus target price of $88.79, indicating a potential upside of 36.00%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.75

Summary

BioMarin Pharmaceutical beats AbCellera Biologics on 14 of the 17 factors compared between the two stocks.

How does AbCellera Biologics compare to Halozyme Therapeutics?

AbCellera Biologics (NASDAQ:ABCL) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

In the previous week, Halozyme Therapeutics had 12 more articles in the media than AbCellera Biologics. MarketBeat recorded 19 mentions for Halozyme Therapeutics and 7 mentions for AbCellera Biologics. Halozyme Therapeutics' average media sentiment score of 1.27 beat AbCellera Biologics' score of 0.65 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	14 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AbCellera Biologics currently has a consensus price target of $12.83, indicating a potential upside of 3.49%. Halozyme Therapeutics has a consensus price target of $91.20, indicating a potential downside of 14.70%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, equities research analysts plainly believe AbCellera Biologics is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

AbCellera Biologics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

Halozyme Therapeutics has a net margin of 24.86% compared to AbCellera Biologics' net margin of -248.83%. Halozyme Therapeutics' return on equity of 260.98% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-248.83%	-17.49%	-12.36%
Halozyme Therapeutics	24.86%	260.98%	23.91%

Halozyme Therapeutics has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	50.61	-$146.41M	-$0.54	N/A
Halozyme Therapeutics	$1.40B	8.69	$316.89M	$3.35	31.92

61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Halozyme Therapeutics beats AbCellera Biologics on 11 of the 17 factors compared between the two stocks.

How does AbCellera Biologics compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

In the previous week, Arrowhead Pharmaceuticals had 10 more articles in the media than AbCellera Biologics. MarketBeat recorded 17 mentions for Arrowhead Pharmaceuticals and 7 mentions for AbCellera Biologics. Arrowhead Pharmaceuticals' average media sentiment score of 1.18 beat AbCellera Biologics' score of 0.65 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	15 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals has higher revenue and earnings than AbCellera Biologics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$669.50M	18.64	-$1.63M	-$2.25	N/A
AbCellera Biologics	$75.13M	50.61	-$146.41M	-$0.54	N/A

Arrowhead Pharmaceuticals presently has a consensus price target of $97.33, indicating a potential upside of 9.87%. AbCellera Biologics has a consensus price target of $12.83, indicating a potential upside of 3.49%. Given Arrowhead Pharmaceuticals' higher possible upside, equities research analysts plainly believe Arrowhead Pharmaceuticals is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Arrowhead Pharmaceuticals has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Arrowhead Pharmaceuticals has a net margin of -47.79% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.49% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
AbCellera Biologics	-248.83%	-17.49%	-12.36%

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Arrowhead Pharmaceuticals beats AbCellera Biologics on 9 of the 17 factors compared between the two stocks.

How does AbCellera Biologics compare to Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

AbCellera Biologics has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	13.10	-$288.28M	-$12.89	N/A
AbCellera Biologics	$75.13M	50.61	-$146.41M	-$0.54	N/A

Madrigal Pharmaceuticals has a net margin of -25.32% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.49% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
AbCellera Biologics	-248.83%	-17.49%	-12.36%

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Madrigal Pharmaceuticals has a beta of -1.01, suggesting that its stock price is 201% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Madrigal Pharmaceuticals currently has a consensus price target of $699.64, indicating a potential upside of 28.68%. AbCellera Biologics has a consensus price target of $12.83, indicating a potential upside of 3.49%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Madrigal Pharmaceuticals is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Madrigal Pharmaceuticals had 9 more articles in the media than AbCellera Biologics. MarketBeat recorded 16 mentions for Madrigal Pharmaceuticals and 7 mentions for AbCellera Biologics. Madrigal Pharmaceuticals' average media sentiment score of 1.33 beat AbCellera Biologics' score of 0.65 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	14 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

AbCellera Biologics beats Madrigal Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get AbCellera Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABCL vs. The Competition

Export

Metric	AbCellera Biologics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.75B	$4.04B	$7.32B	$12.78B
Dividend Yield	N/A	3.62%	2.53%	11.03%
P/E Ratio	-22.96	11.26	271.29	25.71
Price / Sales	50.61	1,425.95	643.60	106.82
Price / Cash	N/A	108.46	79.17	53.57
Price / Book	4.25	16.47	13.01	6.26
Net Income	-$146.41M	-$22.76M	$3.46B	$348.07M
7 Day Performance	9.54%	1.99%	0.98%	0.47%
1 Month Performance	134.40%	13.04%	8.59%	5.19%
1 Year Performance	188.37%	59.10%	26.54%	16.68%

AbCellera Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABCL AbCellera Biologics	2.1939 of 5 stars	$12.40 +1.3%	$12.83 +3.5%	+185.1%	$3.75B	$75.13M	N/A	500
EXEL Exelixis	3.3485 of 5 stars	$54.52 +1.5%	$50.07 -8.2%	+43.5%	$13.51B	$2.44B	17.14	1,077	Positive News Options Volume Analyst Revision
BMRN BioMarin Pharmaceutical	4.9058 of 5 stars	$66.94 -1.1%	$88.83 +32.7%	+11.3%	$12.96B	$3.41B	180.92	3,221	Positive News Analyst Forecast
HALO Halozyme Therapeutics	3.8665 of 5 stars	$107.85 +1.6%	$91.20 -15.4%	+46.1%	$12.24B	$1.40B	32.19	390	Positive News
ARWR Arrowhead Pharmaceuticals	2.1529 of 5 stars	$86.25 -1.4%	$97.33 +12.9%	+306.6%	$12.15B	$829.45M	N/A	400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABCL) was last updated on 8/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbCellera Biologics (ABCL) Competitors

ABCL vs. EXEL, BMRN, HALO, ARWR, and MDGL

How does AbCellera Biologics compare to Exelixis?

Summary

How does AbCellera Biologics compare to BioMarin Pharmaceutical?

Summary

How does AbCellera Biologics compare to Halozyme Therapeutics?

Summary

How does AbCellera Biologics compare to Arrowhead Pharmaceuticals?

Summary

How does AbCellera Biologics compare to Madrigal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL vs. The Competition

AbCellera Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AbCellera Biologics (ABCL) Competitors

ABCL vs. EXEL, BMRN, HALO, ARWR, and MDGL

How does AbCellera Biologics compare to Exelixis?

Do insiders & institutionals have more ownership in EXEL or ABCL?

Is EXEL or ABCL more profitable?

Do analysts recommend EXEL or ABCL?

Which has better valuation & earnings, EXEL or ABCL?

Which has more risk & volatility, EXEL or ABCL?

Does the media refer more to EXEL or ABCL?

Summary

How does AbCellera Biologics compare to BioMarin Pharmaceutical?

Which has more volatility and risk, ABCL or BMRN?

Which has higher earnings and valuation, ABCL or BMRN?

Do institutionals and insiders believe in ABCL or BMRN?

Does the media favor ABCL or BMRN?

Is ABCL or BMRN more profitable?

Do analysts rate ABCL or BMRN?

Summary

How does AbCellera Biologics compare to Halozyme Therapeutics?

Does the media favor ABCL or HALO?

Do analysts prefer ABCL or HALO?

Which has more volatility & risk, ABCL or HALO?

Is ABCL or HALO more profitable?

Which has stronger valuation and earnings, ABCL or HALO?

Do insiders and institutionals believe in ABCL or HALO?

Summary

How does AbCellera Biologics compare to Arrowhead Pharmaceuticals?

Does the media refer more to ARWR or ABCL?

Which has better earnings and valuation, ARWR or ABCL?

Do analysts recommend ARWR or ABCL?

Which has more risk & volatility, ARWR or ABCL?

Is ARWR or ABCL more profitable?

Do insiders & institutionals believe in ARWR or ABCL?

Summary

How does AbCellera Biologics compare to Madrigal Pharmaceuticals?

Which has preferable valuation & earnings, MDGL or ABCL?

Is MDGL or ABCL more profitable?

Do insiders and institutionals hold more shares of MDGL or ABCL?

Which has more risk and volatility, MDGL or ABCL?

Do analysts recommend MDGL or ABCL?

Does the media prefer MDGL or ABCL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL vs. The Competition

AbCellera Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools